

## TABLE OF CONTENTS


	PAGE
ACKNOWLEDGEMENTS	iii
ABSTRACT	v
LIST OF TABLES	xvi
LIST OF ILLUSTRATIONS	xvii
ABBREVIATIONS	xx
<b>CHAPTER I: INTRODUCTION</b>	<b>1</b>
<b>CHAPTER II: LITERATURE REVIEWS</b>	<b>4</b>
1. Human immunodeficiency virus type 1 (HIV-1)	4
1.1 Genomic organization	4
1.2 Virion structure	5
1.3 Cellular targets	7
1.4 Viral tropism	7
1.5 Replication cycle	8
1.5.1 Binding and entry	8
1.5.2 Reverse transcription and DNA synthesis	8
1.5.3 Nuclear transport of the pre-integration complex	8
1.5.4 Proviral DNA integration	8
1.5.5 Viral transcription and protein synthesis	9
1.5.6 Assembly and budding of virus	9
1.6 Mode of transmission of HIV-1	9
1.6.1 Sexual transmission	9
1.6.2 Mother to child transmission	10

1.6.3 Transmission by blood products and contaminated equipment	10
2. Clinical course of HIV-1 infection	10
2.1 Typical progressors	10
2.2 Rapid progressors (RPs)	12
2.3 Long-term nonprogressors (LTNPs)	12
3. Highly exposed persistently seronegative (HEPS) persons	14
4. HIV-1 co-receptors	15
4.1 Chemokines and chemokine receptors	15
4.2 Chemokine receptors and HIV-1 infection	16
4.3 Factors influence on susceptibility to HIV-1 infection and disease progression	16
4.3.1 Host genetic variations	16
4.3.2 Immune mechanism	19
4.3.3 Sexually transmitted diseases (STDs)	21
5. CC-Chemokine receptor 5 (CCR5)	21
5.1 Structure and function of CCR5	21
5.2 Characterization of the CCR5 gene	22
5.3 Variation in the coding region of CCR5 gene	25
5.3.1 CCR5 $\Delta$ 32	25
5.3.2 CCR5-m303	26
5.3.3 CCR5-893(-)	26
5.3.4 Additional coding region variants of the CCR5 gene	27
5.4 Variation in the promoter region of CCR5 gene	29
<b>CHAPTER III: RESEARCH DESIGN, MATERIALS AND METHODS</b>	<b>32</b>
1. Research design	32
2. Materials	35
2.1 Study populations	35
2.2 Oligonucleotide primers	35
2.3 Antibodies	38

3. Methods	38
3.1 Sample collection and storage	38
3.2 DNA preparation	39
3.2.1 Isolation of the PBMCs	39
3.2.2 Extraction of the genomic DNA	39
3.2.3 Quantitation of the purified genomic DNA	40
3.3 Determination of nucleotide polymorphisms in the promoter region of the CCR5 gene	40
3.3.1 Amplification of the CCR5 promoter region by PCR	40
3.3.2 Cloning of the CCR5 promoter region	41
3.3.2.1 Purification of the PCR product	41
3.3.2.2 Ligation of the purified CCR5 promoter fragment	42
3.3.2.3 Transformation of the recombinant plasmid DNA	42
3.3.2.4 Screening for the recombinant plasmid DNA in the transformed bacteria	42
3.3.3 Sequencing of the CCR5 promoter region	43
3.3.3.1 Purification of the plasmid DNA	43
3.3.3.2 Quantity of purified recombinant plasmid DNA	44
3.3.3.3 Dye terminator cycle sequencing	44
3.3.3.4 Purification of the sequencing products	45
3.3.3.5 Long-Read Tower™ sequencer analysis	45
3.3.3.6 Analysis of the nucleotide polymorphism of CCR5 promoter sequences	46
3.4 Determination of the CCR5 $\Delta$ 32 genotype	46
3.4.1 Amplification of the CCR5 ORF by PCR	46
3.5 Determination of the CCR5-m303 genotype	46
3.5.1 Amplification of the CCR5 ORF by Nested-PCR	47
3.5.2 Detection of the CCR5-m303 genotype by Restriction Enzyme Analysis (REA)	47
3.6 Determination of the CCR5 protein density on surface of CD4+	48

lymphocytes and monocytes	
3.6.1 Determination of CCR5 on the surface of CD4+ T lymphocytes	48
3.6.2 Determination of CD14 and CCR5 molecules on the surface of white blood cells	49
3.6.3 Flow cytometric analysis	49
3.6.4 Quantitative determination of the CCR5 protein density on the surface of CD4+ lymphocytes and monocytes	51
3.6.5 Statistical analysis	51
<b>CHAPTER IV: RESULTS</b>	52
1. Study subjects	52
2. Determination of nucleotide polymorphisms in the promoter region of the CCR5 gene	54
2.1 Amplification of the CCR5 promoter region by PCR technique	54
2.2 Cloning of the CCR5 promoter/enhancer region	56
2.3 The polymorphism of CCR5 promoter region	59
2.4 Analysis of the nucleotide polymorphisms of CCR5 promoter region	88
3. Determination of the CCR5 $\Delta$ 32 genotype	91
4. Determination of the CCR5-m303 genotype	93
5. Determination of the CCR5 protein density on surface of CD4+ T lymphocytes and monocytes	97
5.1 Expression of the membrane CCR5 on CD4+ T lymphocytes	97
5.2 Expression of the membrane CCR5 on monocytes	100
5.3 Calibration curve	103
5.4 CCR5 density on surface of CD4+ lymphocytes	106
5.5 CCR5 density on surface of monocytes	109
<b>CHAPTER V: DISCUSSION</b>	112

CHAPTER VI: SUMMARY	118
REFERENCES	120
APPENDICES	130
CIRRICURUM VITAE	145



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright© by Chiang Mai University  
All rights reserved

## LIST OF TABLES

Table		Page
1	Genetic variations of the coding region of CCR5 gene	28
2	CCR5P alleles	30
3	Primer information	36
4	Characteristics and laboratory studies of the HIV-1 serodiscordant subjects and the normal control subjects in the study	53
5	Comparison of the multisite alleles of the CCR5 promoter gene of 19 HEPS subjects with Martin <i>et al.</i> (1998)	89
6	Comparison of the multisite alleles of the CCR5 promoter gene of 16 HIV-1 seropositive subjects with Martin <i>et al.</i> (1998)	90

## LIST OF ILLUSTRATIONS

Figure		Page
1	Virion structure and genomic organization of HIV-1	6
2	Schematic representation of the decline in CD4 <sup>+</sup> T lymphocytes and the kinetics of viremia during the various courses of HIV-1 infection observed in typical progressors (TPs), rapid progressors (RPs) and long-term nonprogressors (LTNPs)	13
3	The schematic structure and genomic organization of CCR5	24
4	CCR5 polymorphisms; the map of the reported polymorphisms found in the CCR5 promoter and coding region	31
5	The schematic diagram presenting the research design of the study	34
6	The location of R5-PF, R5-PR, R5-32F, R5-32R, R5-303F, and R5-303R primers in the CCR5 gene	37
7	The nucleotide sequences and <i>HincII</i> recognition site (GTY <sup>*</sup> RAC) of wild type and mutant allele	48
8	Illustration of EDTA whole blood stained with the specific antibodies	50
9	Illustration of the PCR amplification products of the promoter/enhancer region of the CCR5 gene using R5-PF and R5-PR primers	55
10	Illustration of DNA extracted from the bacterial colonies after selected by growing on the medium containing 100 µg/ml of ampicillin	57
11	PCR amplification product of CCR5 promoter region from the 4.2 kb of the recombinant clones using R5-PF and R5-PR primers	58
12	The electrophoregram of the nucleotide sequence in the CCR5 promoter region of the HEPS (H07) on forward direction using Modified M13 Universal primer	60

13	The electrophoregram of the nucleotide sequence in the CCR5 promoter region of the HEPS (H07) on backward direction using R5-PR primer	64
14	Comparison of the CCR5 promoter sequences obtained from the HEPS subjects with the corresponding position 58,548 to 59,737 of CCR5 sequences accession number U95626 submitted in the GenBank database	68
15	Comparison of the CCR5 promoter sequences of 16 HIV-1 seropositive subjects with the corresponding position 58,548 to 59,737 of CCR5 sequences accession number U95626 submitted in the GenBank database	78
16	PCR amplification of the CCR5 ORF by specific primers flanking with the CCR5 $\Delta$ 32 region	92
17	First round amplification of the CCR5 ORF by R5-303F and R5-303R primers	94
18	Second round amplification of the CCR5 ORF by R5-303NF and R5-303NR primers	95
19	Detection of the CCR5-m303 genotype by cleavage of a 737 bp PCR product with <i>HincII</i> restriction endonuclease	96
20	CCR5 expression on CD4 <sup>+</sup> T lymphocytes of HEPS subjects (H03, H10, and H14), HIV-1 seropositive subjects (P02, P10, and P14), and normal subjects (N03, N06, and N08) as analyzed by flow cytometry using anti-CCR5 PE and anti-CD4 FITC	98
21	Percentage of CCR5 <sup>+</sup> CD4 <sup>+</sup> cells in total lymphocytes population from HEPS, HIV-1 seropositive, and normal subjects	99
22	CCR5 expression on monocytes (CD14 <sup>+</sup> ) of HEPS subjects (H03, H10, and H14), HIV-1 seropositive subjects (P03, P10, and P14), and normal control subjects (N03, N06, and N08) as analyzed by flow cytometry using anti-CCR5 PE and anti-CD14 FITC	101
23	Percentage of CCR5 <sup>+</sup> on CD14 <sup>+</sup> cells in total monocytes from HEPS subjects, HIV-1 seropositive subjects, and normal control subjects	102
24	Determination of the QuantiBRITE™PE standard quantitation beads by CellQuest software	104



25	Calibration curve. The calibration curve obtained from the geometric means of fluorescence intensities of the four bead peaks (mean fluorescence intensity against number of PE molecules per bead)	105
26	Fluorescence intensity of the CD4+ T lymphocytes expressed CCR5 molecule of HEPS subjects (H10, H14, and H18), HIV-1 seropositive subjects (P01, P14, and P15), and normal control subjects (N05, N09, and N10) as analyzed by flow cytometry using anti-CCR5 PE and anti-CD4 FITC	107
27	CCR5 density on CD4+ T lymphocytes from HEPS, HIV-1 seropositive, and normal control subjects	108
28	Fluorescence intensity of the monocytes expressed CCR5 molecule of HEPS subjects (H01, H07, and H14), HIV-1 seropositive subjects (P02, P11, and P18), and normal control subjects (N01, N03, and N07) as analyzed by flow cytometry using anti-CCR5 PE and anti-CD14 FITC	110
29	CCR5 density on monocytes from HEPS, HIV-1 seropositive, and normal control subjects	111


## ABBREVIATIONS

%	percent
$\alpha$	alpha
$\beta$	beta
$\Delta$	delta
$\gamma$	gamma
$\mu$	micro
$\mu\text{g}$	microgram
$\mu\text{l}$	microliter
$\mu\text{M}$	micromolar
$^{\circ}\text{C}$	degree Celsius
AIDS	acquired immune deficiency syndrome
bp	base pair
CCR5	CC-chemokine receptor 5
CD	cluster of differentiation
cDNA	complementary deoxyribonucleic acid
CTLs	cytotoxic T-lymphocytes
CXCR4	CXC- chemokine receptor 4
dATP	deoxyadenosine triphosphate
dCTP	deoxycytidine triphosphate
ddNTP	dideoxynucleotide triphosphate
dGTP	deoxyguanosine triphosphate
DNA	deoxyribonucleic acid
dNTP	deoxynucleotide triphosphate
dTTP	deoxythymidine triphosphate
EIA	enzyme immunoassay

ELISA	enzyme linked immunosorbent assay
EDTA	ethylenediaminetetraacetic acid
FACS	fluorescence-activated cell sorter
FITC	fluorescein isothiocyanate
g	gram or gravity
HEPS	highly exposed persistently seronegative
HIV	human immunodeficiency virus
IFN	interferon
Ig	immunoglobulin
IgA	immunoglobulin A
IgE	immunoglobulin E
IgG	immunoglobulin G
IL	interleukin
kb	kilobase
kDa	kiloDalton
LTNP	long-term nonprogressor
M	molarity
mAb	monoclonal antibody
mAbs	monoclonal antibodies
mg	milligram
ml	milliliter
mM	millimolar
N	normality
ng	nanogram
nm	nanometer
OD	optical density
ORF	open reading frame
PBMC	peripheral blood mononuclear cells
PCR	polymerase chain reaction
PE	phycoerythrin

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
 Copyright © by Chiang Mai University  
 All rights reserved

REA	restriction enzyme analysis
RNA	ribonucleic acid
RP	rapid progressor
rpm	revolutions per minute
STD	sexually transmitted disease
TNF	tumor necrosis factor
U	unit



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright© by Chiang Mai University  
All rights reserved